OTCMKTS:DTCFF Defence Therapeutics (DTCFF) Stock Price, News & Analysis $0.46 0.00 (0.00%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort Interest Get Defence Therapeutics alerts: Email Address About Defence Therapeutics Stock (OTCMKTS:DTCFF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Defence Therapeutics alerts:Sign Up Key Stats Today's Range$0.46▼$0.4650-Day Range$0.40▼$0.6652-Week Range$0.40▼$2.30Volume3,000 shsAverage Volume878 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDefence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Read More… How the US Will Win the Great Lithium Race (Ad)China spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but it processes 70-80%. Now the US is coming over the top by investing $700B+ into domestic supply with the IRA and Bi-partisan Infrastructure Bill.Join GM as an early investor in this company by October 3. Receive DTCFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DTCFF Stock News HeadlinesDefence Therapeutics (OTCMKTS:DTCFF) Stock Price Down 14.6%September 17 at 3:53 AM | americanbankingnews.comDefence Therapeutics Inc. (DTC.F)August 20, 2024 | ca.finance.yahoo.comAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing?September 20, 2024 | InvestorPlace (Ad)Defence Therapeutics Inc. (DTCFF)July 30, 2024 | finance.yahoo.comDefence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline GrowthApril 17, 2024 | finance.yahoo.comDefence Therapeutics Inc.: Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing UpdateFebruary 29, 2024 | finanznachrichten.deDefence Therapeutics Completes 1st Tranche of FinancingJanuary 30, 2024 | finance.yahoo.comDefence FinancingJanuary 19, 2024 | finance.yahoo.comSee More Headlines DTCFF Stock Analysis - Frequently Asked Questions How have DTCFF shares performed this year? Defence Therapeutics' stock was trading at $1.65 at the start of the year. Since then, DTCFF stock has decreased by 72.2% and is now trading at $0.4590. View the best growth stocks for 2024 here. How do I buy shares of Defence Therapeutics? Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:DTCFF CUSIPN/A CIKN/A Webdefencetherapeutics.com Phone514 947 2272FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (OTCMKTS:DTCFF) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Defence Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Defence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
